For example, RES inhibits the NF-κB pathway and promotes the expression of Sirt1 by inhibiting the activity of FAK (21); EGCG can downregulate glucose-regulated protein 78 (GRP78) expression and activate the NF-κB/mir-155-5p pathway, therefore inhibiting the resistance of colon cancer cells to chemotherapeutic drugs (13); and pristimerin can induce apoptosis and inhibit cell proliferation by inhibiting the Akt/forkhead box protein O (FOXO3a) pathway (41). This evidence concerns the gene NFKB1 and malignant colon neoplasm.